Where disease protection is lacking, PaxVax sees opportunity

There is a great, unmet need for vaccines that help protect against infectious disease in both developed and developing countries. Additionally, there is an opportunity to focus on vaccines that protect against diseases in categories such as travel. Addressing these needs was the inspiration for the creation of PaxVax.

How it all began

The 2005 H5N1 influenza pandemic scare put in focus the lack of an ideal vaccine for pandemic preparedness. In May of 2005, the future founders of PaxVax discussed practical approaches to address this glaring gap in global immunization readiness by brainstorming ways to develop scalable, affordable, oral vaccines that could be made available to people worldwide.

In the 1960s, Ad4 and Ad7 adenovirus vaccines were developed by the United States military to help prevent these two serious strains of this respiratory tract disease in their recruits. The attributes of Ad4 and Ad7 – replication competence, oral delivery, and well-established safety and efficacy– made them attractive candidates as vaccine vectors. This idea of using the Ad4/Ad7 vaccine vector as a platform to develop other needed vaccines was the basis for the founding of PaxVax.

In 2006, the founders of PaxVax had a goal of transforming the vaccine industry with revolutionary new platforms to meet the growing global demand for protection against infectious diseases.

A fully integrated vaccine company

By successfully executing on a strategy of organic growth and acquisition, PaxVax today is a fully integrated specialty vaccine company with approximately 200 employees working at locations in the United States, Europe and Bermuda. The company is led by a Board of Directors and management team that includes some of the industry’s most seasoned vaccine experts and leaders.

PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California, USA, and Thörishaus, Switzerland. The San Diego facility is the base of operations for the company’s R&D program and is where Vaxchora™ production, quality testing, product release and supply chain management happen. In Switzerland, the PaxVax site is on 36 acres and includes multiple manufacturing, office and lab spaces. Vivotif® production, quality testing, product release and supply chain all happen at this site.

PaxVax is initially focused on delivering vaccines for the travelers markets. An estimated 100 million people (families, students, workers and soldiers) per year travel to developing countries where tropical diseases are endemic and vaccines are needed for protection.

To date, PaxVax has raised more than $200 million (USD) from investors including Cerberus Capital Management, Ignition Ventures, Ignition Growth and the Wellcome Trust. We are also supported by R&D grants and contracts from the U.S. National Institutes of Health (NIH) through both its National Institutes of Allergy and Infectious Diseases (NIAID) and Division of AIDS (DAIDS) as well as the Bill & Melinda Gates Foundation.